[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100351962":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":47,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Leiden University Medical Center","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with (suspicion of) primary EOC",null,[12],"Other: No intervention",{"label":14,"type":10,"description":10,"interventionNames":15},"Patients with recurrent EOC",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"No intervention","Observational study, no intervention",[9,14],[22],{"name":23,"affiliation":5,"role":24},"Judith R Kroep, MD PhD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+31715263464","j.r.kroep@lumc.nl",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"A F de Groot, MD","+31715299126","a.f.de_groot@lumc.nl",[35],{"facility":5,"status":36,"city":37,"state":10,"zip":10,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Leiden","Netherlands",{"type":40,"coordinates":41},"Point",[42,43],4.49306,52.15833,{"lat":43,"lon":42},[46],{"name":23,"role":27,"phone":10,"phoneExt":10,"email":10},{"type":24,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"J.R. Kroep","Principal Investigator MD PhD","100351962",false,"NCT03862677","Determining Prognostic Immune Markers in Patients With Ovarian Cancer","IMPrOVE","Inclusion Criteria:\n\n* Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and\u002For immunotherapy.\n* Age ≥18 years.\n* WHO performance status 0-2.\n* Accessible for treatment and follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.\n* Any known severe infection like HIV, hepatitis A, B and C.\n* Receiving immune suppressive treatment.\n* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.","FEMALE","18 Years",{"count":59,"type":60},300,"ESTIMATED","OBSERVATIONAL","The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).",[64],"Epithelial Ovarian Cancer",[66,67,68,69,70,54,71,72],"Epithelial ovarian cancer","Fallopian tube cancer","Primary peritoneal cancer","EOC","Immunity","Prognostic","Immune markers","2026-02-12",{"date":75,"type":76},"2026-02-13","ACTUAL",{"date":78,"type":76},"2020-08-15",{"date":80,"type":60},"2027-01-31",{"name":5,"class":6},1]